Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Invested Capital (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Invested Capital for 16 consecutive years, with $143.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Invested Capital fell 6.83% to $143.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $143.5 million, a 6.83% decrease, with the full-year FY2025 number at $143.5 million, down 6.83% from a year prior.
  • Invested Capital was $143.5 million for Q4 2025 at Anika Therapeutics, down from $146.8 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $303.7 million in Q2 2021 to a low of $143.5 million in Q4 2025.
  • A 5-year average of $235.8 million and a median of $272.3 million in 2023 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: grew 5.28% in 2021, then plummeted 33.5% in 2024.
  • Anika Therapeutics' Invested Capital stood at $291.4 million in 2021, then decreased by 2.0% to $285.6 million in 2022, then decreased by 25.67% to $212.3 million in 2023, then decreased by 27.45% to $154.0 million in 2024, then decreased by 6.83% to $143.5 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Invested Capital are $143.5 million (Q4 2025), $146.8 million (Q3 2025), and $147.7 million (Q2 2025).